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Abstract: The TWIK-related spinal cord potassium channel (TRESK) is encoded by KCNK18, and
variants in this gene have previously been associated with susceptibility to familial migraine with
aura (MIM #613656). A single amino acid substitution in the same protein, p.Trp101Arg, has also been
associated with intellectual disability (ID), opening the possibility that variants in this gene might
be involved in different disorders. Here, we report the identification of KCNK18 biallelic missense
variants (p.Tyr163Asp and p.Ser252Leu) in a family characterized by three siblings affected by mild-
to-moderate ID, autism spectrum disorder (ASD) and other neurodevelopment-related features.
Functional characterization of the variants alone or in combination showed impaired channel activity.
Interestingly, Ser252 is an important regulatory site of TRESK, suggesting that alteration of this
residue could lead to additive downstream effects. The functional relevance of these mutations and
the observed co-segregation in all the affected members of the family expand the clinical variability
associated with altered TRESK function and provide further insight into the relationship between
altered function of this ion channel and human disease.
Keywords: KCNK18; TRESK; K2P; intellectual disability; potassium channel; autism spectrum
disorder; ASD
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1. Introduction
KCNK18 encodes the TWIK-Related Spinal cord K+ channel (TRESK), a member of
the two-pore domain (K2P) potassium channel family. K2P channels count 15 members,
encoded by different KCNK genes [1]. At the protein level, these channels have different
names according to their structural and functional similarities. They are classified into the
TWIK, TREK, TASK, TALK, THIK and TRESK subfamilies [2].
The molecular architecture of the TRESK channel resembles other K2P channel sub-
types except that it has a longer intracellular loop between the second and the third
transmembrane domains and a shorter C-terminal tail. The intracellular loop contains fun-
damental modulatory sites such as phosphorylation, dephosphorylation and calcineurin
binding motifs. Under resting conditions, murine TRESK is phosphorylated and maintains
an inactive conformation, but, after a calcium signal, the channel is rapidly activated
following dephosphorylation by the calcium-dependent phosphatase calcineurin [3,4].
To allow this process, calcineurin must bind to the channel through interaction with its
non-catalytic sites, helped by the regulatory protein, 14-3-3. In humans, the process is also
supported by protein kinase C (PKC) [3]. The switch between the active and resting states
has been intensely investigated [4] and it is mediated by the phosphorylation of TRESK at
two different regulatory regions, the 14-3-3 binding site (Serine 252, Ser252, hereafter) and
three adjacent serine residues (Ser262, Ser264 and Ser267, collectively named serine cluster,
hereafter). These residues are conserved in murine TRESK as Ser264, Ser274, Ser276 and
Ser279.
The activated calmodulin complex stimulates the binding of calcineurin to the TRESK
intracellular loop, thus promoting dephosphorylation of the two regulatory residues
(Ser252 and the serine cluster) and the activation of the channel. After the decay of
the calcium signal, channel activity is inhibited by the restoring of the phosphorylated
state by protein kinase A, which acts at the level of Ser252, and microtubule affinity-
regulating (MARK) kinases, which mediate phosphorylation at the level of the serine
cluster, supported by 14-3-3 proteins [4].
Interestingly, a high basal activity and reduced response to calcium have been reported
in a study using a murine TRESK mutant characterized by a constitutively dephosphory-
lated state of the serine cluster [4]. Remarkably, prolonged phosphorylation of this motif
has been shown to cause reduced responsiveness of the channel and low basal activity [4,5],
further documenting the complex modulatory process controlling TRESK function.
KCNK18 expression in the dorsal root (DRG) and trigeminal (TG) ganglia [6] led to a
proposed role for this channel in a variety of pain pathways [7]; moreover, an involvement
in typical migraine with aura has been suggested by different authors [8–11]. Despite the
expression of KCNK18 in the basal ganglia, its mRNA is detectable also in other brain
compartments, including the hypothalamus, frontal cortex, cortex, anterior cingulate
cortex, hippocampus, spinal cord and substantia nigra (www.gtexportal.org (accessed on
22 April 2021)), suggesting a wider involvement of the channel in physiological brain
function. Interestingly, recent studies have also reported KCNK18 variants in patients with
developmental delay (DD) and intellectual disability (ID), with migraine as an associated
feature in some cases [12,13]. Here, we describe the identification of a family with three
siblings affected by mild to moderate ID, seizures, and autistic-like behavior with different
degrees of severity, carrying biallelic KCNK18 variants, supporting a possible involvement
of the gene in neurodevelopmental disorders (NDD).
2. Results
2.1. Clinical Features of the Three Affected Siblings
A family of European origins, with three siblings affected by an unclassified NDD, was
studied (Figure 1A). The parents had no history of NDD or of any notable diseases, except
for a carcinoma in the mother. The first proband was a 26-year-old female at the time of the
last evaluation. Born at term after cesarean delivery, the proband showed a delay in the
acquisition of developmental milestones, with the first phonemes at 18 months, walking
Int. J. Mol. Sci. 2021, 22, 6064 3 of 13
at 24 months and sphincter control at 5 years. Mild ID was reported (total IQ—64, verbal
IQ—60, performance IQ—70), with difficulties in calculation and inability to recognize the
value of money. Poor language, dysarthria and attention deficit were observed. Moreover,
partial temporal–spatial disorientation, poor criticism, and judgment with limitation of
the possibilities of self-determination were reported. The support from a caretaker was
required for everyday activity and for self-care. She suffered frequent (once a week)
frontal cephalalgy. At clinical examination, the behaviour was uncooperative and restless.
Even if autism spectrum disorder was not formally assessed using the Autism Diagnostic
Observation Schedule (ADOS-2), nor using other behavioural tests, the patient showed an
important impairment of relationships that, combined with the other symptoms, led the
physician to include her in the autism spectrum.
The second born proband was a 19-year-old female diagnosed with a mild ID (total
IQ—56, verbal IQ—47, performance IQ—76). The patient showed compromised social
relations that, as with her sister, included the patient into a clinical diagnosis of autism
spectrum disorder. Specific difficulties in the logical-mathematical area were reported,
together with the inability to remember new concepts. The support from a second person
was necessary for everyday activity. An episode of epileptic seizure was reported and
supported by electroencephalography (EEG), which showed comitiality.
The last born was a 16-year-old male affected by dyslexia and difficulties in learning,
but no further information were available.
The social-economic situation of the family was also taken into account, to understand
if the impaired behaviour of the patients could be caused by a combination of genetic and
environmental factors [14,15]; no noteworthy situation was identified, except for a worsen-
ing of the already poor social behaviour of the patients after the death of their mother.
2.2. Genomic and Structural Analyses
The patients were enrolled in the Autism Sequencing Consortium (ASC) project [16],
and a WES of the whole family members performed. In the three affected members, the
analysis led to the identification of compound heterozygosity for two missense changes
(c.487T > G, p.Tyr163Asp, paternally inherited; c.755C > T, p.Ser252Leu, maternally in-
herited) (Figure 1A). Both variants affected residues that are highly conserved among
orthologs (Figure 1B) and were predicted to have a disruptive impact on protein function
(Table S1). Variant p.(Tyr163Asp) had not previously been reported in GnomAD database
(ver 2.1.1) (www.gnomad.broadinstitute.org (accessed on 22 April 2021)), while variant
p.(Ser252Leu) had an allelic frequency of 0.0001379 at the time of the analysis; both the
variants were not previously reported in our in-house databases. Both affected residues are
located within the intracellular domains of the channel (Figure 1C), a region that plays a
key role in the conformational switching events controlling TRESK function [5]. Of note,
Ser252 plays an important regulatory role in the switching process by cycling between
its phosphorylated and dephosphorylated states [5]. The highly conserved nature of the
two residues and their predicted location consistently supported the functional relevance
of the two amino acid substitutions. WES data analysis excluded the occurrence of other
functionally relevant variants compatible with known Mendelian disorders based on the
expected inheritance model and clinical presentation, further supporting the relevance of
the two missense variants involving KCNK18.





Figure 1. Pedigree, conservation, and graphical representation of the KCNK18 variants. A. Pedigree of the family and 
Sanger sequencing chromatograms documenting co-segregation between compound heterozygosity for the two missense 
changes in KCNK18 and clinical traits transmitted in the family. B. Multiple alignments of the amino acid stretches 
flanking the affected residues in TRESK orthologs showing conservation of both mutated residues (in red). Residues are 
referred to human KCNK18, NM_181840.1. C. Schematic topology of the human K2P TRESK channel, showing location 
of Tyr163 (Y163) and Ser252 (S252) (red asterisks). Human TRESK is composed of 384 amino acid residues and shows the 
most characteristic features of K2P channels, including four transmembrane helices, two pore-forming domains, and 
intracellular N- and C-termini. A peculiar structural feature of TRESK (compared to other K2P channels) is the long 
intracellular loop between the second and third transmembrane segments (TMS), and the relatively short C-terminal tail 
[3]. In the image, representative domains are shown: PQIIIS and LQLP are calcineurin-binding motifs [5,17], while the 
serine cluster and Ser252 are indicated by the letter S and are, respectively, MARK kinases and 14-3-3 and PKA binding 
motifs. 
  
Figure 1. Pedigree, conservation, and graphical representation of the KCNK18 variants. (A). Pedigree of the family and
Sanger sequencing chromatograms documenting co-segregation between compound heterozygosity for the two missense
changes in KCNK18 and clinical traits transmitted in the family. (B). Multiple alignments of the amino acid stretches
flanking the affected residues in TRESK orthologs showing conservation of both mutated residues (in red). Residues are
referred to huma KCNK18, NM_181840.1. (C). Sche atic topology of the human K2P TRESK channel, showing l cation of
Tyr163 (Y163) and Ser252 (S252) (red asterisks). H man TRESK is composed of 384 amino acid residues and shows the most
characteristic features of K2P channels, including four tr nsmembrane helices, two pore-forming dom ins, and intracellular
N- and C-termini. A peculiar structural feature of TRESK (compared to other K2P channels) is the long intracellular loop
between the second and third transmembrane segments (TMS), and the relatively short C-terminal tail [3]. In the image,
representative domains are shown: PQIIIS and LQLP are calcineurin-binding motifs [5,17], while the serine cluster and
Ser252 are indicated by the letter S and are, respectively, MARK kinases and 14-3-3 and PKA binding motifs.
2.3. p.Tyr163Asp and p.Ser252Leu Do Not Alter Basal TRESK Function Genomic and
Structural Analyses
To validate the in silico predictions, we next examined whether the two missense
changes in KCNK18 affect the functional properties of TRESK. Figure 2A shows representa-
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tive whole-cell basal currents recorded from Xenopus oocytes injected with mRNA encoding
human wild-type (WT) or the mutant TRESK channels. All channel types exhibited sim-
ilar outwardly rectifying K+ current amplitudes, but the current in oocytes expressing
TRESKS252L was slightly larger (Figure 2A,B). This larger basal K+ current, which is not
statistically different, could be due to a reduction in the phosphorylation state of the mutant
channel compared to TRESKWT. However, a robust gain of function in the basal K+ current
has been observed when a serine close to the cluster was replaced with an alanine. Given
that the K2P channels work as dimers, to mimic the compound heterozygous condition
of affected subjects, equal amounts of the KCNK18 mutated mRNAs were co-injected
into oocytes at a 1:1 ratio. Co-injection of mutant mRNAs did not substantially affect
the whole-cell basal currents, which had similar amplitudes to those reported in oocytes
overexpressing WT TRESK (Figure 2A,B). TRESK channels typically produce a leak K+
current that stabilizes the resting membrane potential [13]. We observed that the expression
of WT TRESK or both mutants, expressed separately or together, shifted the resting cell
membrane potential of the oocytes towards the K+ equilibrium potential (EK) (Figure 2C).
Assuming an intracellular K+ concentration of approximately 140 mM in the oocyte, the
predicted value for EK is −107 mV. A similar hyperpolarizing effect was observed upon
expression of all TRESK channel types (Figure 2C). Collectively, these findings indicate that
both mutations do not dramatically change the basal activity of TRESK channels, which
also retain their ability to control the cell’s resting potential.
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 5 of 13 
 
 
2.3. p.Tyr163Asp and p.Ser252Leu Do Not Alter Basal TRESK Function Genomic and 
Structural Analyses 
To validate the in silico predictions, we next examined whether the two missense 
changes in KCNK18 affect the functional properties of TRESK. Figure 2A shows 
representative whole-cell basal currents recorded from Xenopus oocytes injected with 
mRNA encoding human wild-type (WT) or the mutant TRESK channels. All channel types 
exhibited similar outwardly rectifying K+ current amplitudes, but the current in oocytes 
expressing TRESKS252L was slightly larger (Figure 2A,B). This larger basal K+ current, 
which is not statisticall  different, could be due to a reduction in the phosphorylation state 
of the mutant channel compared to TRESKWT. However, a robust gain of function in the 
bas l K+ current has been obs rved when a seri e close to the cluster was r placed with 
an ala ine. Given that the K2P channels w rk as dimers, to mimic the compo nd 
heterozygous condition of affect d subjects, equal amounts of the KCNK18 mutated 
mRNAs were co-i jected into oocytes at a 1:1 ratio. Co-injection of mutant mRNAs did 
not substantially affect the whole-cell basal currents, which had similar amplitudes to 
those report d in oocytes overexpressing WT TRESK (Figure 2A,B). TRESK channels 
typically produce  leak K+ current that stabilizes the resting membran  potential [13]. We 
observ d that the expression of WT TRESK or both mutants, expressed separately or 
together, shifted the resting cell membrane potential of the oocytes towards th  K+ 
equilibrium potential (EK) (Figur  2C). Assuming an intracellular K+ concentration of 
approximat ly 140 mM in the oocyte, the predicted value for EK is −107 mV. A similar 
hyperpolarizi g effect was observed upon expression f all TRESK channel types (Figure 
2C). Collecti ely, these findings indicate that both mutations do not dramatically change 
the basal activity of TRESK channels, which also retain their ability to control the cell’s 
resting potential.  
 
Figure 2. p.Tyr163Asp and p.Ser252Leu do not significantly affect the basal current and ability of 
TRESK channels to control the cell’s resting potential. A. Representative families of current traces 
for the indicated channel types. Cell membrane potential was held at −80mV. Each family of 
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Figure 2. p.Tyr163Asp and p.Ser252Leu do not significantly affect the basal current and ability of
TRESK channels to control the cell’s resting potential. (A). Representative families of current traces
for the indicated channel types. Cell membrane potential was held at 80mV. Each fa ily of currents
was evoked by voltage steps from −120 mV to 60 mV, with 20 mV increments. The recordings were
pe formed 48 h after the injection of 1 ng of mRNA for each channel type. (B). Average IV relationships
calculated from experiments as in A for the labelled chan el types (color co ed). The data points are
mean ± standard error (0.001; n = 12). (C). Resting membrane potentials from individual oocytes
un-injected (grey dots), injected with 1 ng of WT (black dots) or Y163D (green dots) or S252L (blue dots)
or 0.5 ng of each Y163D and S252L (red dots) mRNA and recorded 48 h after injection. Note that the
expression of all channel types similarly shifts the resting potential toward K+ reversal potential. The
dots in C represent single cell recordings. The data are mean ± standard deviation.
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2.4. p.Tyr163Asp and p.Ser252Leu Impair the Ability of TRESK to Properly Respond to
Calcineurin Activation
Given that the variants lie in amino acids located in regions important for the calcineurin-
dependent gating of the channel, we next examined whether the mutant channels retain
the ability to respond to calcineurin activation. In WT TRESK channels expressed in
Xenopus oocytes, an increase in intracellular Ca2+ produced by the calcium ionophore
ionomycin generally results in strong calcineurin-dependent activation of TRESK [5,18].
We therefore determined the effect of ionomycin on WT TRESK and the identified variants.
As expected, 0.5 µM ionomycin induced a large, robust, and reversible activation of WT
TRESK (Figure 3A). By contrast, we found that ionomycin was much less effective in
the activation of homomeric and heteromeric mutant channels (Figure 3A). Indeed, the
absolute values of Ca2+-activated whole-cell currents were significantly smaller than that
for the WT channel (Figure 3B; WT vs. all groups p < 0.001). Moreover, we found that
the extent of activation (IIono/IBasal ratios) for both homomeric and heteromeric TRESK
channels was much smaller compared to that observed for the WT channel (Figure 3C).
However, due to the relatively small amplitude of the unstimulated IBasal currents for the
TRESKY163D and TRESKS252L mutants, these values may be overestimated. The response of
un-injected control oocytes to ionomycin was insignificant, as previously reported [13,19]
(Figure 3A–C) and all groups showed an obvious difference in the ionomycin-induced
current when compared to un-injected oocytes (Figure 3B; WT vs. un-injected p < 0.001;
Y163D vs. un-injected p = 0.02; S252L and Y163D + S252L vs. un-injected p < 0.01). The
relatively small ionomycin-induced current amplitude recorded from mutants, in particular
from Y163D, could be responsible for the misleading reduced level of significance when
compared with that of control un-injected oocytes.
Overall, these results indicate that although the identified disease-associated KCNK18
variants do not alter the basal activity of TRESK, both markedly impair the ability of the
channel to respond to calcineurin activation.
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period of the steady-state currents recorded at −100 mV. Ionomycin activates the WT channels but has little effect on the 
oocytes that express the mutant channels or those that are uninjected. Note that the current decay upon reapplication of a 
solution containing 2 mM K+ in the recording chamber is due to the reduced K+ concentration rather than ionomycin 
washout. B. Bar graph showing the mean of ionomycin activated currents (*** p < 0.001). All the groups were statistically 
significant compared to the uninjected group (WT vs. uninjected p < 0.001; Y163D vs. uninjected p = 0.02; S252L and Y163D 
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Figure 3. KCNK18 p.Tyr163Asp and p.Ser252Leu impair the ionomycin-induced activation of TRESK channels. Repre-
sentative data points showing ionomycin activation of TRESK WT, Y163D, S252L and Y163D + S252L currents as well as
endogenous currents from un-injected oocytes. (A). Currents were evoked by 300 ms long voltage steps from 0 mV to −100
mV from oocytes injected with 1 ng of mRNA of the corresponding and indicated homomeric channel type and 0.5 ng for
each subunit for the heteromeric channel Y163D/S252L. The sampled data represent the average of 50 ms long period of
the steady-state currents recorded at −100 mV. Ionomycin activates the WT channels but has little effect on the oocytes
that express the mutant channels or those that are uninjected. Note that the current decay upon reapplication of a solution
co taining 2 mM K+ in the r cording chamber is due to the reduced K+ conc ntration rather than ionomycin washout. (B).
Bar graph showing the mean of ionomycin ctivated currents (*** p < 0.001). All the groups were statis ically significant
compared to the uninjected group (WT vs. uninjected p < 0.001; Y163D vs. uninjected p = 0.02; S252L and Y163D + S252L
vs. uninjected p < 0.01; n = 12). (C). Each point represents the steady state ionomycin activated current divided by the
steady-state basal current (IIono/IBasal) recorded in the presence of 80 mM extracellular K+.
3. Discussion
TRESK background K+ channel contributes to the stabilization of the resting mem-
brane pote tial of sensory neurons, particularly at the level of dorsal root and trigeminal
ganglia [20,21]. Variants in the KCNK18 gene have been frequently associated with mi-
graine [9,11,13,22]. Interestingly, patients with ID, with or without migraine, have also
been reported [12,13], suggesting a contribution of dysregulated TRESK function in NDDs.
In the frame of a large genome scan project focused on patients with NDDs [16], we
identified a family of European origin with three siblings affected by ID. In the oldest case
(patient 1), recurrent episodes of migraine were also reported. In this family, WES allowed
the identification of a new compound heterozygosity for two missense variants (Tyr163Asp
and Ser252Leu) in all affected siblings. The variant occurring on residue Ser252 caught
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our attention, as it has been largely demonstrated that this residue is fundamental for the
regulation of TRESK, being subjected to reversible phosphorylation, regulating the acti-
vation of the channel [4,23,24]. In pharmacophore-based virtual screening to reveal novel
inhibitors against migraine, it has also been suggested Ser252 is one of the binding sites for
Ergotamine and Lasmiditan, two drugs commonly used for migraine treatment [25].
To functionally validate the pathogenic relevance of the identified amino acid substi-
tutions on TRESK function, electrophysiological recordings using Xenopus oocytes were
performed. Slightly larger whole-cell basal K+ current amplitudes were observed in oocytes
expressing TRESKS252L, which could be attributed to a reduction in the phosphorylation
state of the mutant channel compared to TRESKWT. Indeed, a similar effect has been
reported when the serine in position 276 (TRESKS276A) in the rat clone was replaced
with an alanine [26]. On the other hand, the substitution of serine 276 with a glutamate,
mimicking the dephosphorylated state, resulted in a mutant with low basal activity and
reduced responsiveness. Interestingly, TRESKS276A also shows a reduced response to
calcium signals. The S252 residue is part of the binding motif for 14-3-3, a family of ubiqui-
tous adapter/regulatory proteins involved in the phosphorylation/dephosphorylation-
dependent regulation of the channel. It has been shown that the 14-3-3γ isoform directly
binds to the intracellular loop of TRESK and controls the kinetics of the calcium-dependent
regulation of the channel [23].
Notably, 14-3-3γ plays a role in neuronal migration, morphology and brain develop-
ment [27]. The gene encoding this protein (YWHAG) has been associated to developmental
and epileptic encephalopathy (OMIM #717665), and autistic traits have been described in
affected patients [28]. It is, therefore, intriguing to hypothesize that the S252L variant could
cause an alteration in the interaction with 14-3-3γ, impairing its downstream activity and
altering the same pathways involved in YWHAG-related disorders [28].
Here, we demonstrated that both the Y163D and S252L variants remarkably affect
the TRESK response to intracellular Ca2+, which is able to cause calcineurin-dependent
activation of the channel [5,18]. Specifically, while ionomycin induced a large and re-
versible activation of the WT channel, this activation was strongly reduced by the two
variants, in both homomeric and heteromeric mutant channels. The exact location of both
variants in the TRESK channel cannot be determined due to the lack of any 3D structural
information on the regulatory domain of TRESK channels. However, in the linear sequence,
Y163 is located nearby the calcineurin binding site. It could, therefore, be hypothesized
that its substitution with aspartate (Y163D), a negatively charged residue, could disrupt
calcineurin-channel interactions, and abolish current activation (Figure 3).
It is worth noting that the impairment of the channel activation after ionomycin
induction (Figure 3) is not representative of the effect of the variants in the parents, as
both the constructs were not expressed in combination with the WT one. With these
experiments, we are, therefore, more likely mimicking a homozygous state of the variants
instead of the heterozygous state observed in the parents. This is also in line with the higher
impairment of the channel activation observed with Y163D and S252L alone compared to
their combination.
The TRESK subfamily consists of only one member (KCNK18, K2P18.1) that has been
cloned from the human spinal cord [29]. TRESK was shown to be expressed in rodent
cerebrum, cerebellum, brain stem and, spinal cord [5]. Published evidence and data
retrieved from the Allen Brain Atlas (www.portal.brain-map.org/ (accessed on 22 April
2021)) and GTEx Portal (www.gtexportal.org (accessed on 22 April 2021)) clearly show high
expression of TRESK channels in human brain regions, for some of which the impairment
has been associated with autism and ID [30]. How mutations in the TRESK channels
identified so far [12,13] alter the functionality of these brain areas and result in autism
and ID remains to be investigated. Whatever the final impact on the human brain of the
mutations described here, which disrupt the calcineurin-dependent regulation of TRESK,
may be, some insights could be gained by considering the effects of calcineurin inhibitors.
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Indeed, Cyclosporin A and FK506 are inhibitors of the calcium/calmodulin-dependent
protein phosphatase calcineurin, which abolish calcium-dependent TRESK activation.
Neurological complications of Cyclosporin therapy are frequent and include dysarthria,
headache, restlessness and seizures. Neurologic toxicity related to therapy with Tacrolimus
(FK506), a macrolide calcineurin inhibitor, has also been reported, including restlessness,
agitation, confusion, sleep problems, mental depression, dysarthria, headache and seizures.
Intriguingly, dysarthria, restlessness, headache and seizures have been observed in our
patients and it is tempting to speculate that these symptoms could be associated, at least in
part, with Y163D- and S252L-induced disruption of calcineurin-dependent TRESK channel
activation in the brain. Recently, it has been proposed that calcineurin regulation of two-
pore potassium-leak channel activity (Kcnk5b) mediates activation of developmental gene
transcription, which controls a broad number of developmental pathways [31]. Similarly
to TRESK channels, inwardly rectifying K+ channels (Kir) control the resting potential of
neurons and K+ homeostasis in the brain. Previous findings showed the importance of
several Kir channel types in neurodevelopment, autism and ID [32–38]. Thus, growing
evidence shows that K+ dependent bioelectric mechanisms can regulate not only the
excitability of neurons, but also cell migration, proliferation, differentiation and gene
transcription, thereby promoting coordinated developmental signaling.
In summary, our study suggests that the KCNK18 variants observed in our patients
dramatically impair the ability of the TRESK channel to respond to calcineurin activa-
tion, leading to the alteration of a crucial function of the channel. Indeed, acetylcholine,
glutamate or histamine activate native TRESK currents through G-protein coupled recep-
tors [39], and this function would be nearly abolished by both Y163D and S252L variants.
Collectively, our findings strengthen the notion that abnormal TRESK channel function
in the central and peripheral nervous system could play crucial roles in neurologic and
psychiatric diseases. Further studies on larger cohorts of patients and the characterization
of transgenic animal models of the disease are, however, required to elucidate the link
between migraine, autism, epilepsy and intellectual disability observed in some patients
carrying TRESK variants.
4. Materials and Methods
4.1. Whole Exome Sequencing, Prioritization, and Variant Calling
DNA was extracted from total blood using the ReliaPrep Blood gDNA Miniprep kit
(Promega, Madi-son, WY, USA) following the manufacturer’s protocol and quantified with
a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Array-
CGH was performed using a 60 K whole-genome oligonucleotide microarray (Agilent
Technologies, Santa Clara, CA, USA).
Patients were enrolled in the Autism Sequencing Consortium (ASC) project and their
gDNA samples were sequenced at the Broad Institute on Illumina HiSeq sequencers, as
previously described [16,40].
Whole exome sequencing (WES) raw data of the trio were processed and analyzed
using an in-house implemented pipeline that has been previously described [41,42], which
is based on the GATK Best Practices [43]. The UCSC GRCh37/hg19 version of genome
assembly was used as a reference for reads alignment by means of the BWA-MEM [44]
tool and the subsequent variant calling with HaplotypeCaller (GATK v3.7) [43]. We
used SnpEff v.4.3 [45] and dbNSFP v.3.5 [46] tools for variants functional annotation,
including Combined Annotation Dependent Depletion (CADD) v.1.3 [47], Mendelian
Clinically Applicable Pathogenicity (M-CAP) v.1.0 [48] and Intervar v.0.1.6, for functional
impact prediction [49]. Thereby, the analysis was narrowed to variants which affect coding
sequences or splice site regions. Moreover, high-quality variants were filtered against
public databases (dbSNP150 and gnomAD ver.2.0.1) so that only variants with unknown
frequency or with MAF <0.1%, as well as variants occurring with frequency <1% in our
population-matched database (~2000 exomes), were considered.
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Further variant stratification in conformity with the American College of Medical Ge-
netics and Genomics (ACMG) guideline [50], considering also the mode of inheritance and
functional in-silico prediction of impact, allowed us to consider the final set of variants for
possible associations with the phenotype. All variants are referred to GRCh37 annotation
and to NM_181840.1.
Identified variants were confirmed by Sanger sequencing using standard conditions
and the following primers: 5′-GGGAGATGGCAGAAGGTCTCTTTA and 5′-TTACTCCTCT
CCATGGCTTGTGG; 5′-CAAACTTGGCACATGTCCTTCAC and 5′-GCATGACCCTGAAA
GACAACACA.
Variants were analysed with the VarSome tool [51] as a starting point for further
analysis. This allowed simultaneous evaluation of at least nine in silico predictors. Variants’
frequencies in the population were evaluated using the Genome Aggregation Database
(GnomAD), browser version 2.1.1.
4.2. Constructs
Human TRESK was subcloned between the 5′ and 3′ UTR of the Xenopus β-globin
gene in the oocyte expression vector, pFAW. The identified variants were introduced by site
directed mutagenesis and confirmed by automated sequencing. mRNA for wild-type and
mutant channels was synthesized using the T7 mMESSAGE mMACHINE kit (Ambion,
Life technologies, Carlsbad, CA, USA) and mRNA concentrations were quantified by
spectrophotometric analysis prior to injection.
4.3. Electrophysiological Recordings
Xenopus laevis oocytes collection and defolliculation were performed according to
standard protocols which fall under the international standards of animal care, the Maltese
Animal Welfare Act and the NIH Guide for the Care and Use of Laboratory Animals.
TRESK wild-type or mutant mRNAs were microinjected into oocytes in equal quantities,
unless otherwise stated. Forty-eight hours after injection, whole-cell currents were recorded
at room temperature (20–22 ◦C) using the two-electrode voltage clamp method (Axoclamp-
2B, Axon DIGIDATA 1550B, Axon Instruments, Foster City, CA, Axon). Basal K+ currents
were measured in a low K+ extracellular solution (in mM: 95.4 NaCl, 2 KCl, 1.8 CaCl2,
5 HEPES pH 7.5 with NaOH). Recording electrodes (0.3÷1 MΩ) were backfilled with
3 M KCl. Currents were filtered at 100 Hz and digitized at 1 kHz for analysis. From
a holding potential of −80 mV, 1-second-long voltage commands were applied from
−120 mV to +60 mV, delivered in 20 mV increments. Currents were recorded using
Clampex 10.7 software (Axon Instruments, Foster City, CA, USA). Ionomycin-induced
TRESK currents were measured in high K+ solution (in mM: 17.4 NaCl, 80 KCl, 1.8 CaCl2,
5 HEPES, pH 7.5 with NaOH) at the end of 300 ms-long voltage steps from a holding
potential of 0 mV to −100 mV. Ionomycin (free acid form) was made as a stock solution of
1 mM in DMSO and diluted in the high K+ solution to 0.5 µM on the day of the experiment.
Data were analyzed with Clampfit 10.7 (Axon instruments, Foster City, CA, USA) and
Igor programs.
4.4. Statistics
Data are given as mean values± standard error of the mean (SEM), where n represents
the number of oocytes. Results were reproducible in at least 2–3 different batches of oocytes.
Statistical significance was determined using a student’s t-test. When error bars are not
shown, they are smaller than the size of the symbol.
4.5. Online Resources
www.gtexportal.org, accessed on 22April 2021
www.gnomad.broadinstitute.org, accessed on 22 April 2021
www.portal.brain-map.org, accessed on 22 April 2021
www.varsome.com, accessed on 22 April 2021.
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